Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
Weight-loss Drugs
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
Rapid weight reduction might raise the risk of osteoporosis and reduce muscular mass. However, there is now excellent news for those who may be at danger when taking weight loss medications. According to a recent study from Aarhus University, the adverse effects can be mitigated by the medication bimagrumab.
In 2022–2023, the researchers found people diagnosed with obesity without diabetes using a nationwide sample of medical insurance claims data from over 17 million persons with private insurance.
